Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a report published on Thursday.

Several other brokerages also recently issued reports on TEVA. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Barclays boosted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Trading Down 0.3 %

Shares of TEVA stock opened at $17.96 on Thursday. The company has a market cap of $20.35 billion, a PE ratio of -46.05, a price-to-earnings-growth ratio of 1.20 and a beta of 0.88. Teva Pharmaceutical Industries has a 1 year low of $8.06 and a 1 year high of $19.08. The stock’s 50 day simple moving average is $17.95 and its two-hundred day simple moving average is $16.59. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Research analysts predict that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of the stock. Sequoia Financial Advisors LLC raised its position in Teva Pharmaceutical Industries by 0.7% during the second quarter. Sequoia Financial Advisors LLC now owns 111,575 shares of the company’s stock valued at $1,813,000 after acquiring an additional 826 shares in the last quarter. Edmond DE Rothschild Holding S.A. boosted its holdings in Teva Pharmaceutical Industries by 4.0% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 24,495 shares of the company’s stock worth $346,000 after buying an additional 947 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in Teva Pharmaceutical Industries by 9.6% during the first quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock valued at $191,000 after buying an additional 1,180 shares during the period. QRG Capital Management Inc. increased its holdings in Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after buying an additional 1,191 shares in the last quarter. Finally, United Services Automobile Association raised its position in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after acquiring an additional 1,249 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.